Why Is Avantor (AVTR) Down 13.6% Since Last Earnings Report?

Core Viewpoint - Avantor, Inc. has experienced a decline in share price by approximately 13.6% since its last earnings report, underperforming the S&P 500, raising questions about its future performance leading up to the next earnings release [1] Financial Performance - For Q4 2025, Avantor reported adjusted earnings per share of 22 cents, an 18.5% decrease year-over-year, but exceeded the Zacks Consensus Estimate by 4.8% [2] - Revenues for the quarter totaled $1.66 billion, down 1.4% year-over-year, yet surpassed the Zacks Consensus Estimate by 3% [3] - The gross profit declined 6.9% year-over-year to $523.9 million, with a gross margin contraction of 190 basis points to 31.5% [8] - Adjusted operating profit was $225.4 million, reflecting a 19.3% decrease from the prior-year quarter [9] Segment Analysis - The Laboratory Solutions segment reported net sales of $1.12 billion, a decrease of 0.9% year-over-year, with organic sales down 4.1% [4] - The Bioscience Production segment's net sales were $547.5 million, down 2.4%, with organic sales also decreasing by 4.1% year-over-year [6] Guidance and Outlook - For 2026, Avantor projects organic revenue growth to be between negative 2.5% and negative 0.5%, with expectations that the VWR distribution business will modestly outperform Bioscience and Medtech Products [12] - Adjusted earnings per share guidance for 2026 is set between 77 cents and 83 cents, below the Zacks Consensus Estimate of 89 cents [14] Market Position and Competitors - Avantor's stock has a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [17] - In comparison, Cencora, a competitor in the same industry, reported revenues of $85.93 billion for the last quarter, reflecting a year-over-year increase of 5.5% [19]